M&A Deal Summary

Allergan Acquires Chase Pharmaceuticals

On November 22, 2016, Allergan acquired life science company Chase Pharmaceuticals from Edmond de Rothschild Private Equity for 125M USD

Acquisition Highlights
  • This is Allergan’s 21st transaction in the Life Science sector.
  • This is Allergan’s 16th largest (disclosed) transaction.
  • This is Allergan’s 21st transaction in the United States.
  • This is Allergan’s 1st transaction in District of Columbia.

M&A Deal Summary

Date 2016-11-22
Target Chase Pharmaceuticals
Sector Life Science
Buyer(s) Allergan
Sellers(s) Edmond de Rothschild Private Equity
Deal Type Add-on Acquisition
Deal Value 125M USD
Advisor(s) Cowen (Financial)
Hogan Lovells (Legal)

Target

Chase Pharmaceuticals

Washington, District of Columbia, United States
Chase Pharmaceuticals Corporation, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase's development program, if successful, will profoundly improve the symptomatic treatment of Alzheimer's disease.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Allergan

Parsippany, New Jersey, United States

Category Company
Founded 1956
Sector Life Science
Employees31,200
Revenue 15.8B USD (2018)
DESCRIPTION

Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.


DEAL STATS #
Overall 31 of 38
Sector: Life Science M&A 21 of 23
Type: Add-on Acquisition M&A Deals 25 of 31
State: District of Columbia M&A 1 of 1
Country: United States M&A 21 of 27
Year: 2016 M&A 8 of 9
Size (of disclosed) 16 of 25
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-11 SERI Surgical Scaffold

Parsippany, New Jersey, United States

SERI Surgical Scaffold is a provider of silk based solutions to treat patients with soft-tissue defects.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-20 LifeCell

Branchburg, New Jersey, United States

LifeCell Corp. is a provider of applications in plastic and reconstructive surgeries and abdominal wall procedures.

Buy $2.9B

Seller(S) 1

SELLER
DESCRIPTION

Edmond de Rothschild Private Equity is the private equity arm of asset manager and financial services firm Edmond de Rothschild. The private equity group looks seeks buyout and expansion style investments and will consider opportunities across the world, including North America, Europe, and Africa. The Firm broadly invests in real estate, infrastructure projects, and directly in companies. Edmond de Rothschild Private Equity is based in Geneva, Switzerland.


DEAL STATS #
Overall 19 of 27
Sector: Life Science M&A 5 of 5
Type: Add-on Acquisition M&A Deals 8 of 10
State: District of Columbia M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2016 M&A 2 of 2
Size (of disclosed) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-20 Demeco

St Jean De La Ruelle, France

Demeco is a provider of moving services. The company proposes three kinds of services moving of household goods, administrative and business moves, and industrial transfers. Demeco was founded in 1986 and is based in St Jean De La Ruelle, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-04-28 European Homes

Paris, France

European Homes operates in new-build housing development, including the development of private housing estates, intermediate housing, apartment buildings and to a lesser extent, serviced plots. European Homes was founded in 1973 and is based in Paris, France.

Sell -